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Results: Two hundred seventeen NSCLC patients were 
treated in our center. In fifty cases there was a volume 
reduction, so a "replanning" was outlined. Patients' 
characteristics were: mean age 69.6 years (range 38-92), 
squamous histology 56%, 32% adenocarcinoma, other 12%, 
stage IIIA 58% and IIIB 42%. The median total dose delivered 
was 65.7 Gy with standard fractionation. Median CTV at CT 
simulation and at "replanning" was 125.2 cc and 74.7 cc, 
respectively, with a median reduction of 43.1%. The 
"replanning" has been performed at a median dose of 45 Gy. 
At first follow up, 48 patients were evaluated. Response, 
according to RECIST criteria, was as follow: 2 complete 
responses (4.1%), 33 partial responses (68.8%) and 13 stable 
disease (27.1%). Grade 3 toxicities (CTCAE_4.0) were: acute 
esophageal in 4% of cases, pulmonary 6% (1 case acute and 2 
chronic). With a median follow-up of 20.5 months, there have 
been 15 local (31%) and 22 distant (46%) failures. The 
observed local failures were: in field in 20.8% of cases, 
"marginal" in 6.1% and out of field in 4.1%. The median time 
to local failure, progression free survival and overall survival 
were 8.5, 8.3 and 30.5 months, respectively. The median 
onset of “marginal”, in field, out of field and distant failures 
was 12, 9.2, 7.1 and 7.8 months, respectively. 
 
Conclusion: Our results show that "replanning" during RCT 
has an acceptable local failure rate comparable to literature 
data; in particular, given the low incidence of "marginal" 
failures combined with the low rate of acute toxicity, the 
strategy appears promising, bringing to a method of dose 
escalation aimed at reducing in field failures. 
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Purpose or Objective: To assess the feasibility and safety of 
combined stereotactic body radiotherapy (SBRT) of the 
primary tumor (PT) and concurrent chemoradiation (CCRT) in 
stage III NSCLC, the Hybrid study (single center phase I: 
NCT01933568) was initiated. Primary endpoint is the mean 
lung dose (MLD) associated with 15% chance on radiation 
pneumonitis (RP) ≥ G3 and dyspnea ≥ G3. Secondary 
endpoints are toxicity and disease control. This is the first 
report of adverse events observed. 
 
Material and Methods: Eligible patients had stage III or 
inoperable stage II NSCLC with a peripheral PT < 5 cm. 
Patient received CCRT: 24x2.75 Gy or 24x2.42 on the 
pathological lymph nodes (LN) with daily low dose 
cisplatinum 6 mg/m2 with an overall treatment time of 32 
days. SBRT was delivered in 3 fractions of 14-18 Gy in the 2nd 
week concurrent with CCRT. If the fractionated LN treatment 
plan contributed to the PT dose, the total SBRT dose was 
corrected for accordingly. The MLD was escalated with 2 Gy 
increments using the Time-to-Event Continuous Reassessment 
Method (TITE-CRM) statistical design driven by dose limiting 
toxicity (RP or dyspnea ≥ G3; CTCAE v4) within 12 months 
post treatment. The range of acceptable SBRT fraction doses 
allowed accruing patients in different MLD dose bins. 
 
Results: From March 2013- October 2015 12 patients gave 
informed consent for the trial. One patient was excluded 
after the 1st week of treatment due to a baseline shift of the 
PT towards the mediastinum, causing unacceptable dose to 
the mediastinal organs at risk (OAR) if treated with SBRT. 
Median follow up (FU) was 8 months (range 0-26), median age 
was 63 years (range 61-75), 73% was male, 73% had 
adenocarcinoma, 18% squamous cell carcinoma, 9% large cell 
NOS. 73% had T1 tumors, 9% T2, 18% T3 (2 tumors), 18% N1, 
73% N2 and 9% N3. Ten patients received CCRT, 1 patient 
radiotherapy only due to co-morbidities. No locoregional 
recurrences have been observed. Two patients developed 
distant metastases, one of which died 12 months post 
treatment due to leptomeningeal metastases. Median SBRT 
dose was 53 Gy (range 43-54 Gy) and median LN dose was 
2.75 Gy. Median MLD (α/β=3 Gy) was 11.9 Gy (range 5.2-18 
Gy). In 2 patients SBRT dose was decreased: in 1 patient due 
to allocation in a lower MLD risk group than the treatment 
plan MLD, in 1 patient because of normal tissue constraints of 
the mediastinal OAR. During treatment 4 patient developed 
dysphagia G2, 2 fatigue G2, 1 thrombocytopenia G2, 1 
anorexia G2 and 1 patient hemoptysis G2 . Radiation 
pneumonitis G2 occurred in 1 patient at 2.5 months FU with 
an MLD of 12.4 Gy. One patient developed chest wall pain G2 
due to a rib fracture at 32 months FU. There were no G3-5 
toxicities. 
 
Conclusion: A Hybrid treatment of SBRT of the primary tumor 
combined with concurrent chemoradiation is feasible. This 
phase I trial is currently accruing and no unexpected toxicity 
has been observed thus far.  
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Purpose or Objective: Background The definition of target 
volumes in radiotherapy for Hodgkin lymphoma quickly 
evolved during the last decades, with the comings of 
Involved-field radiotherapy (IF), then the Involved Node 
(IN)1, and more recently the concept of Involved-site (IS)2. 
The latter two concepts are based on the observation that 
recurrences mainly concern the adenopathies present at 
diagnosis when radiotherapy is not performed and on the 
need to reduce the irradiated volumes to limit the radiation-
induced late morbidity. If the H103 and RAPID4 trials 
confirmed the interest of radiotherapy in localized disease, 
the standard technique is still debated. The studies currently 
led by the LYSA illustrate this confusion since one (BREACH) 
made IN its standard technique, while the other (BRAPP2) 
requires IF-radiotherapy.  
To assess routine radiotherapy practices in the treatment of 
localized Hodgkin lymphoma. 
 
Material and Methods: At the initiative of multicentric and 
multidisciplinary working group involving radiation 
oncologists, hematologists, and nuclear medicine physicians, 
